Abstract. Background Small-cell lung cancer (SCLC) classified as early stage at the point of diagnosis is very rare representing only 5% of all SCLC patients (1). The low incidence of early stage SCLC is mainly attributable to highly aggressive biology, rapid tumour growth, the absence of early symptoms and a lack of established screening programs (2, 3).
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Radiochemotherapy remains the standard treatment in limited stage SCLC resulting in a median overall survival of 16-20 months (2-4). Several biomarkers such as survivin and alternatively spliced actinin-4 variant expression have been identified recently to impact the prognosis of patients with SCLC (5, 6). The optimal treatment of early stage SCLC and subgroups of these patients remain an issue of debate. An increasing number of patients with early stage SCLC receive surgical treatment resulting in a favourable median overall survival of 29-91 months (1, 7-9). However, randomised controlled trials comparing different treatment modalities in early stage SCLC are still warranted. Additionally, potential prognostic factors in these patients still remain unclear. This study aimed to identify prognostic factors in patients undergoing standard radiochemotherapy for early stage SCLC.
Patients and Methods
Eight SCLC patients diagnosed stage I or II according to the "Union internationale contre le cancer" (UICC) staging were treated with radiochemotherapy of the primary tumour and involved lymph nodes between 2006 and 2009. Median age was 64 years. Chemotherapy consisted of two to six courses of etoposide (120 mg/m 2 on days 1-3) plus cisplatin (60-80 mg/m 2 on day 1) or carboplatin (AUC 6 on day 1).
The radiation dose was given as equivalent dose in 2 Gy fractions (EQD2). Two EQD2 levels (≤59 vs. >59 Gy, median radiation dose was 59 Gy) and seven factors were evaluated for potential associations with overall survival. These factors were gender, age (<64 vs. ≥64 years, median age=64 years), Karnofsky performance score (≤70 vs. >70), N-category (0 vs. 1), UICC-stage (I vs. II), simultaneous chemotherapy (yes vs. no) and prophylactic cranial irradiation (yes vs. no).
Follow-up visits were conducted every year up to four years, and follow-up time was referred to the end of radiotherapy treatment. Univariate analysis was performed using Kaplan-Meier method and log-rank test (10) . The characteristics that showed a significant association with survival (p<0.05) were included in a multivariate (Cox regression) analysis.
Results
Median overall survival was 46 months after the end of radiotherapy. Detailed survival data are summarized in Table  I . UICC stage I (p=0.022) and performed prophylactic cranial irradiation (p=0.004) were identified as positive prognostic factors in univariate analysis at 4 years. These factors were consequently included in multivariate analysis (Cox regression model). On multivariate analysis, PCI reached significance as independent positive prognostic factor (p<0.001, HR 3.4; 95% CI 1.79-7.1, p<0.001). In contrast, UICC was not significant on Cox regression analysis (p=0.224, HR 0.289, 95% CI 0.018-4.68).
Discussion
Early stage small-cell lung cancer at the point of diagnosis is rare, and optimal treatment for early stage SCLC is controversial. Radiochemotherapy remains the standard treatment for limited staged disease (2), but operative treatment plays an emerging role (1, 7-9). The American College of Chest Physicians (ACCP) recommend a surgical resection followed by platinum-based adjuvant chemotherapy for selected patients with stage I SCLC without nodal involvement as first-line treatment (13) .
Median overall survival in patients treated with multimodal treatment including surgery has been reported to range from 29 to 91 months (1, 7-9). Only two randomised controlled trials have compared surgery and radio(chemo)therapy for SCLC using inadequate chemo-and radiotherapy treatment (11, 12) . Pre-treatment staging opportunities have dramatically changed during the last decade resulting in an improved treatment selection for patients. In our study, median overall survival was 46 months. Earlier studies reported a median overall survival ranging from 22 to 34.6 months in patients with clinical stage I or II SCLC undergoing primary radiochemotherapy (4, 8). Prognostic factors for patients receiving radiochemotherapy for stage I or II SCLC are unclear. Furthermore, a randomized-controlled trial comparing surgery and radiochemotherapy involving state-of-the-art diagnostic and treatment is warranted.
Several studies investigated prognostic factors in patients undergoing surgery (7-9, 14, 15). The Japanese Joint Committee of Lung Cancer Registry performed a nationwide retrospective registry study with 243 patients and suggested several clinical factors to be independent prognostic factors including age, gender and c-stage (14) . Leuzzi et al. suggested that long-term survival might be stratified according to the lymph node-spreading pattern (7).
PCI after thoracic irradiation remains a standard treatment in limited disease SCLC. Youkochi et al. recommended PCI may be useful in patients undergoing surgery for early stage SCLC as a result of a retrospective multicenter analysis (9) . Our study confirmed the prognostic relevance of PCI in patients irradiated for early stage SCLC impacting overall survival.
However, whole-brain irradiation (WBI) can be associated with significant neurocognitive impairment (16) . This effect should be considered critically especially in potential longterm-survivors. Hippocampal sparing offers the opportunity to avoid neurocognitive deficits (16) . Two studies investigated the risk of hippocampal recurrence while using hippocampal sparing WBI and revealed no or minimally evaluated risk of failure compared to standard WBI (17, 18) . Consequently, hippocampal sparing should be seriously considered as a beneficial treatment option when administering PCI. The retrospective nature of the study and the relatively small number of patients must be taken into account when interpreting the results. However, the patients of this study were reviewed at the same pathological department and treated with standardized treatment in a short time interval. This study contributes to improved understanding of prognosis and can guide physicians to find optimal treatment allocations for patients with early stage SCLC.
In conclusion, UICC stage and PCI were identified as significant predictors of survival in early-stage SCLC. PCI was found to be an independent positive prognostic factor and should be performed in patients with early-stage SCLC.
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